What is Heat Biologics, Inc. (HTBX) stock price today?

Heat Biologics, Inc. (HTBX) is currently trading at $2.38, up 0.42% today.

What is HTBX P/E ratio?

Heat Biologics, Inc.'s P/E ratio is -1.87. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is HTBX return on equity (ROE)?

Heat Biologics, Inc.'s return on equity (ROE) is 35.52%, indicating how efficiently the company generates profit from shareholders' equity. This is considered high quality.

What is Heat Biologics, Inc.'s market cap?

Heat Biologics, Inc. has a market capitalization of $61.07M.

AMEX · Biotechnology

Heat Biologics, Inc. (HTBX) Stock

$2.38 +0.42% AMEX: HTBX Healthcare

Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines.

Valuation

Metric	Value
Price	$2.38
Market Cap	$61.07M
P/E Ratio	-1.87
P/B Ratio	-1.09
P/S Ratio	23.67
EPS (TTM)	$-1.41
52-Week High	$10.85
52-Week Low	$1.60
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	35.52%
ROA	-29.54%
ROCE	0.00%
Gross Margin	23.00%
Operating Margin	-1750.00%
Net Margin	-1750.00%
Debt/Equity	-136245.71
Current Ratio	19.80

Annual Financials (USD)

Metric	2017	2018	2019	2020	2021
Revenue	$2.0M	$6.0M	$3.0M	$3.0M	$2.0M
Operating Profit	$-13.0M	$-18.0M	$-21.0M	$-26.0M	$-35.0M
Net Profit	$-12.0M	$-16.0M	$-20.0M	$-26.0M	$-35.0M
EPS	$-21.56	$-6.30	$-4.21	$-1.63	$-1.41
Op Margin	-877.9%	-310.0%	-680.4%	-886.2%	-1676.4%

Balance Sheet (USD)

Metric	2017	2018	2019	2020	2021
Total Assets	$20.0M	$38.0M	$26.0M	$124.0M	$121.0M
Total Liabilities	$14.0M	$8.0M	$13.0M	$9.0M	$9.0M
Cash	$10.0M	$22.0M	$9.0M	$11.0M	$8.0M
Borrowings	$0	$0	$2.0M	$2.0M	$2.0M

Latest News

TowneBank Q2 Earnings, Revenue Rise MT Newswires · Jul 23, 2026 Renault says sales stalled in first half AFP · Jul 23, 2026 Should You Buy Amazon and Meta Platforms Stocks Before July 29? Motley Fool · Jul 23, 2026 argenx Q2 Profit, Total Operating Income Rise MT Newswires · Jul 23, 2026 STMicroelectronics Q2 Non-GAAP Earnings, Revenue Rise MT Newswires · Jul 23, 2026

Cash Flow (USD)

Metric	2017	2018	2019	2020	2021
Operating Cash Flow	$-6.0M	$-22.0M	$-13.0M	$-22.0M	$0
Investing Cash Flow	$-1.0M	$-7.0M	$-1.0M	$-96.0M	$0
Financing Cash Flow	$9.0M	$40.0M	$0	$119.0M	$0
Net Cash Flow	$2.0M	$12.0M	$-13.0M	$2.0M	$0
Free Cash Flow	$-6.0M	$-22.0M	$-13.0M	$-22.0M	$0

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.18
EV / EBITDA	-3.72
FCF Yield	-15967652.00%
Quick Ratio	-0.01
Interest Coverage	8.52
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACHLAchilles Therapeutics plc	$1.48	+0.68%	-0.85	$60.83M	0.00%
ALVRAlloVir, Inc.	$9.81	+4.14%	-1.89	$49.48M	0.00%
HYFT	$1.29	-4.44%	-1.77	$60.61M	0.00%
KRONKronos Bio, Inc.	$0.88	+1.49%	-0.62	$53.65M	0.00%
QNCX	$17.85	-0.03%	-0.05	$4.97M	0.00%

About Heat Biologics, Inc.

Heat Biologics, Inc. is an integrated biopharmaceutical company focused on creating immune-modulating therapies and vaccines. The firm's primary goal is to harness the immune system to fight a variety of illnesses, including both cancerous growths and infectious diseases. A cornerstone of their approach is the gp96 platform, which comprises two key components: ImPACT, an allogenic cell-based system designed to stimulate and proliferate T-cells as an immune activator, and ComPACT, a singular product engineered to achieve both antigen-driven T-cell activation and specific co-stimulation simultaneously. Their development pipeline includes several clinical-stage assets. HS-110 has finished enrolling patients for its Phase II trial targeting advanced non-small cell lung cancer, while HS-130 is currently in a Phase I clinical trial for advanced solid tumors. Furthermore, PTX-35, a novel T-cell co-stimulator agonist antibody that acts on DR3/TNFRSF25, is being evaluated in a Phase I clinical trial for diverse immunotherapy applications. The company is also advancing a COVID-19 vaccine, which is currently in the preclinical stage. Heat Biologics, Inc. has partnered with Dr. James Shapiro at the University of Alberta to develop a surrogate mouse version of PTX-35. The company was founded in 2008 and is headquartered in Morrisville, North Carolina.

Heat Biologics, Inc. is headquartered in US.

Heat Biologics, Inc. (HTBX) stock trades at $2.38 with a market capitalization of $61.07M. The stock is valued at a price-to-earnings (P/E) ratio of -1.87, price-to-book of -1.09, price-to-sales of 23.67. Over the past 52 weeks the stock has ranged between $1.60 and $10.85, and currently trades 78.1% below its 52-week high.

On profitability, Heat Biologics, Inc. generates a return on equity (ROE) of 35.52% — well above the market average, a sign of a high-quality business, return on capital employed of 0.00%, an operating margin of -1750.00%, a net profit margin of -1750.00%.

Official website: www.heatbio.com

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks All stock screens

Run Stock Screener Investing Guides